Results 201 to 210 of about 26,994,982 (307)

The Impact of the Exposome on Epithelial Barriers: New Approach Methodologies for Translational Research. [PDF]

Thorac Res Pract
Saglam-Metiner P, Calkan-Yildirim E, Dogan B, Vaizoglu RD, Celik CE, Goksel O, Yesil-Celiktas O, Pelit L, Kaymaz Y, Kløverpris H, Kwon DS, Kim CF, Koutrakis P, Akdis C, Yilmaz OH, Goksel T.   +15 more
europepmc   +1 more source

1st New approach methodologies report

1st New approach methodologies reportThis report will summarize results from 5.2 on the endpoints ED, (D)NT, NGtx-carc, immunotox, metabolic disruption. The report will give details on the developed NAMs and on the follow-up action to be taken to make the methods robust enough that regulators accept the results.
openaire   +1 more source

Comprehensive Assessment of Arterial, Tissue, and Venous Collaterals for Evaluating the Infarct Growth Rate: The Multimodal Collateral Score

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Collaterals are crucial factors that influence the infarct growth rate (IGR). We aimed to determine whether a comprehensive multimodal collateral score (MCS), incorporating collateral assessment at the arterial, tissue, and venous levels, is associated with functional independence and provides incremental prognostic value over ...
Giorgio Busto, Umberto Pensato, Ilaria Casetta, Giorgio U. Marcello, Angelo Barra, Anna Poggesi, Edoardo Carlesi, Sara Mancini, Andrea Ginestroni, Vittorio Miele, Alessandro Padovani, Andrea Morotti, Enrico Fainardi   +12 more
wiley   +1 more source

Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni, Cecile Pagan, Antony Citterio‐Quentin, Isabelle Rouvet, Giulia Dingeo, Cyril Hanin, Claudine Laurent‐Levinson, Samia Pichard, Bénédicte Héron, Clément Gourguechon, Daniele Mandia, Jerome Guitton, Carole Lacout, Nicolas Schleinitz, Florient Potier, Olivier Flabeau, Elsa Besse‐Pinot, Foudil Lamari, Magali Pettazzoni, Yann Nadjar   +19 more
wiley   +1 more source

Defining benchmarking in the context of safety assessment of personal care and cosmetic products using New Approach Methodologies. [PDF]

NAM J
Huang H, Costin GE.
europepmc   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Neurovascular Contacts in the Pathophysiology of Neuralgic Amyotrophy: An Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuralgic amyotrophy (NA) is a prevalent, monophasic, multifocal immune‐mediated neuropathy. A distinctive characteristic of the disease is the occurrence of nerve or fascicle constrictions and torsions (NA‐associated focal nerve lesions, NAFL). The pathophysiology underlying this phenomenon remains to be fully elucidated.
Johannes Fabian Holle, Andreas Leha, Volker Limmroth, Wolfram Windisch, Maximilian Zimmermann   +4 more
wiley   +1 more source

New Approach Methodologies and Risk Assessment - prospects, challenges and current developments

Tralau,Tewes
core  

New approach methodologies (NAMs) to support regulatory assessment of developmental immunotoxicity - a new PARC project. [PDF]

Front Toxicol
Smith NM, de Bruijn VMP, Vandebriel RJ, Hargitai R, Lumniczky K, Janssen AWF, Beekmann K, Usta B, Tigges J, Spruck C, Hurem S, Iulini M, Corsini E, Bado-Nilles A, Beaudouin R, Katsiadaki I, Cano I, Sebire M, Ayuk HS, Stojanovska V, Zenclussen AC, Blanc EB, Kerdine-Römer S, Lacerda R, Romão L, Monfort-Lanzas P, Gostner JM, Mposhi A, Turner JD, Del Favero G, Lindeman B.   +30 more
europepmc   +1 more source